Argininosuccinic Aciduria Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Expansion of Newborn Screening and Earlier Case Finding

Newborn screening serves as a key driver of patient identification in the argininosuccinic aciduria market. In 2024, Norway expanded its newborn screening program to include distal urea cycle defects, including argininosuccinic aciduria (ASA), increasing the total number of screened congenital diseases to 39. A 2025 Chinese study of 101 patients with urea cycle disorders found that newborn screening identified 57% of cases. Patients identified through screening received a diagnosis within the first month of life, while those diagnosed following symptom onset received diagnoses significantly later. In a separate Chinese cohort of patients with ASL deficiency, late-onset patients identified through newborn screening had a median age at diagnosis of 3 months, compared with 3.5 years for patients identified after symptom onset. Earlier diagnosis enables timely implementation of dietary management, supplementation, and nitrogen-scavenger therapy. As diagnostic programs expand, healthcare systems must ensure the availability of reliable confirmatory testing and timely access to treatment.

Transition From Brand-Only Nitrogen Scavenging to Multisource Supply

Multisource supply is reshaping the treatment economics of the argininosuccinic aciduria market. Endo launched the first U.S. generic version of Ravicti, glycerol phenylbutyrate oral liquid, in October 2025. Lupin received U.S. Food and Drug Administration approval for glycerol phenylbutyrate oral liquid in May 2026. Lupin reported that the reference product generated annual sales of USD 337 million for the year ended December 2025. The entry of additional suppliers can improve patient access where insurance coverage restricts the use of branded products. However, it may also erode branded-product revenue and increase payer emphasis on generic substitution. Zevra reported USD 0.8 million in OLPRUVA revenue for full-year 2025 and subsequently reduced its commercial investment, underscoring the challenges of driving product uptake without clear clinical differentiation.

ASL-Targeted RNA, Exosome, Gene-Editing, and Gene-Transfer Research

Research platforms targeting ASL deficiency represent a potential long-term opportunity for the argininosuccinic aciduria market. In 2024, a study evaluated lipid nanoparticle-delivered CRISPR adenine base editors in hepatocytes derived from patients with the Finnish founder ASL variant. The study reported a 1,000-fold reduction in argininosuccinic acid levels and identified no detectable off-target edits in the tested model. Another 2024 study demonstrated that hASL mRNA delivered through lipid nanoparticles restored ureagenesis and corrected glutathione dysregulation in neonatal and adult ASL-deficient mice. These findings support the development of therapeutic approaches that address oxidative stress alongside ammonia control. A WIPO patent application, reportedly published in December 2025, covers mRNA therapies encoding ASS1 and ASL polypeptides for urea cycle disorders. These programs remain in preclinical or early-stage clinical development and do not replace established disease management practices.

Persistent Neurocognitive and Liver Disease Creates Demand Beyond Ammonia Control

Persistent neurological and hepatic effects represent a significant unmet need in the argininosuccinic aciduria market. A 2025 Chinese cohort study of patients with ASL deficiency reported developmental delay in 87% of survivors and liver dysfunction at presentation in 70% of patients with early-onset disease. These outcomes were observed even when ammonia levels were controlled, demonstrating that hyperammonemia does not fully capture the disease burden. Research in ASL-deficient mice identified glutathione dysregulation as a treatment-relevant mechanism. Consequently, programs that evaluate neurological or hepatic outcomes may establish a differentiated clinical evidence base compared with products focused solely on ammonia reduction. However, current evidence does not support an approved therapy for these residual effects.

Ultra-Rare Patient Pool Limits Commercial Trial Economics

The limited patient pool presents significant challenges to development economics in the argininosuccinic aciduria market. Available evidence estimates U.S. incidence at 1 in 218,750 births, restricting the number of patients eligible for disease-specific clinical studies. This limited population prolongs patient recruitment timelines and constrains the ability to recover development costs through treatment volumes. As a result, sponsors may pursue programs that address multiple urea cycle disorders, including ASA. For instance, Korro’s KRRO-121 targets hyperammonemia across urea cycle disorder genotypes rather than ASA alone. Zevra’s anticipated USD 0.8 million in OLPRUVA revenue in 2025 further underscores the difficulty of achieving commercial scale within a small treated population.

Diagnostic Heterogeneity and Underdiagnosis Obscure Treatable Demand

Clinical variability can delay diagnosis and limit the addressable patient population in the argininosuccinic aciduria market. Early-onset disease may manifest shortly after birth with hyperammonemia and neurological deterioration, while late-onset disease may present with developmental delay, epilepsy, or liver dysfunction, sometimes without elevated ammonia levels. A 2025 Chinese cohort study found that 71.4% of patients were diagnosed after symptom onset rather than through newborn screening. The study also reported that late-onset patients in the screened group developed symptoms between 8 months and 6 years of age despite normal ammonia levels in newborn screening results. The authors recommended adding argininosuccinic acid measurement to screening panels, as citrulline alone may not identify all cases.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Argininosuccinic Aciduria Market Segment Analysis

Early-onset ASA is projected to account for 55.4% of disease-onset revenue in 2026. The need for rapid intervention in this patient group, driven by the risk of neurological deterioration from neonatal hyperammonemia, supports sustained treatment demand. Patients typically initiate dietary management, arginine supplementation, and nitrogen-scavenger therapy shortly after diagnosis. This requirement for continuous treatment establishes a durable demand base in the argininosuccinic aciduria market. In the 2025 Chinese ASL-deficiency cohort, 70% of early-onset patients presented with liver dysfunction, reinforcing the need for follow-up care beyond acute ammonia reduction.

The late-onset ASA segment is forecast to grow at a CAGR of 5.6% through 2032. This segment includes adolescents and adults who may remain undiagnosed until molecular testing or symptom-based evaluation occurs. In the Chinese cohort, late-onset patients who did not undergo newborn screening had a median diagnosis age of 13 years, compared with 3 months among newborn-screened late-onset patients. In addition to nitrogen control, late-onset management may require neurological monitoring and liver surveillance. As diagnosis increasingly occurs beyond the neonatal period, the argininosuccinic aciduria market requires care pathways that address the long-term needs of these patients.

Newborn screening-identified cases are expected to generate 60.5% of diagnosis-pathway revenue in 2026. Screening reduces the time from birth to diagnosis and facilitates earlier referral of infants to specialist care. In 2024, Norway added distal urea cycle defects, including ASA, to its national screening panel, increasing the program's coverage to 39 congenital diseases. In China, a study of 101 patients with urea cycle disorders reported that newborn screening identified 57% of cases. As screening programs continue to expand, they are expected to establish a more consistent referral flow into the argininosuccinic aciduria market.

Molecularly confirmed cases are forecast to grow at a CAGR of 5.8% through 2032. Molecular confirmation supports the identification of patients with atypical presentations that may not be detected through initial screening profiles, particularly those with mild biochemical abnormalities or later-onset symptoms. The Chinese ASL-deficiency study found that normal ammonia levels during newborn screening did not prevent symptom development in some late-onset patients. Molecular testing also enables providers to differentiate ASL deficiency from other causes of neurological or hepatic symptoms. Symptom-diagnosed cases will remain relevant in regions with limited newborn screening coverage. Accordingly, the argininosuccinic aciduria market will continue to depend on both screening and clinical evaluation pathways.

Nitrogen scavengers accounted for 46.8% of treatment-modality revenue in 2026. Glycerol phenylbutyrate remains a well-established option for the long-term management of urea cycle disorders. This drug class is used in combination with dietary restrictions and supplementation, rather than as a standalone treatment. A Spanish urea cycle disorder registry reported that 48 patients who transitioned to glycerol phenylbutyrate achieved improved metabolic control and experienced fewer adverse effects^[1]. Medical nutrition therapy, protein restriction, and arginine or citrulline supplementation continue to form an integral part of care across disease severities. As a result, the argininosuccinic aciduria market is supported by a multimodal treatment model.

Liver transplantation-linked care is projected to grow at a CAGR of 6.4% through 2032. A 2025 Chinese cohort study of patients with ASL deficiency found that 27.6% underwent liver transplantation. The study reported normalized ammonia levels and liver function in all transplanted patients. The median age at transplantation was 11 months, highlighting the potential for transplant evaluation during infancy when medical therapy is inadequate. Transplantation-linked care includes patient evaluation, perioperative management, post-transplant follow-up, and immunosuppression. Acute hyperammonemia rescue remains a critical component of care when oral management does not adequately control a metabolic crisis.

Glycerol phenylbutyrate oral liquid is projected to account for 55.8% of product revenue in 2026, with the glycerol phenylbutyrate segment of the argininosuccinic aciduria market expected to expand at a CAGR of 5.9% through 2032. The product offers practical benefits for long-term treatment, particularly a lower administration volume than sodium phenylbutyrate tablets. OrphanPacific plans to launch Ravicti in Japan in April 2026 following its national health insurance listing. This launch is expected to expand treatment access for Japanese patients with urea cycle disorders and support demand for the leading product.

However, generic competition is expected to erode the leading product's exclusivity. Endo plans to launch a generic glycerol phenylbutyrate oral liquid in the United States in October 2025, while Lupin is expected to receive FDA approval for another generic version in May 2026. Sodium phenylbutyrate products will continue to serve as established alternatives in cost-sensitive formularies. Although Zevra expects OLPRUVA to reach 81% of covered lives and generate USD 0.8 million in revenue in 2025, the outcome indicates that formulary coverage alone may not drive meaningful product uptake. Medical foods and specialized formulas will remain essential where nutritional management forms a core component of patient care.

Metabolic Disease Centers accounted for 62.6% of end-user revenue in 2026. These centers serve as the primary point of care for ASA diagnosis, treatment initiation, and long-term patient monitoring. They also coordinate dietary counseling, specialist prescribing, and laboratory follow-up, positioning them as a core component of the argininosuccinic aciduria market. By comparison, tertiary hospitals focus on managing acute hyperammonemia and intensive inpatient care requirements. Patients identified through screening may require hospital-based stabilization during early life. Referral networks between hospitals and metabolic centers facilitate continuity of care across treatment settings.

Specialty Pharmacies and Home Care are forecast to grow at a CAGR of 6.9% through 2032. The long-term nature of treatment is driving demand for delivery models that provide rare-disease medicines and nutritional products directly to patients’ homes. In 2024, Orsini established a metabolic disorder center of excellence with a dedicated urea cycle disorder program. Home delivery helps reduce the logistical burden associated with recurring prescriptions and dietary products. Specialty channels also manage limited-distribution products and coordinate prescription refills. These services complement, rather than replace, the clinical oversight provided by metabolic centers. Consequently, the argininosuccinic aciduria industry is evolving toward an integrated care model that combines specialist prescribing with home-based product supply.

Oral administration is projected to account for 68.8% of route-of-administration revenue in 2026. Glycerol phenylbutyrate and sodium phenylbutyrate are available in oral formulations for chronic treatment, enabling patients to manage the condition outside hospital settings. A 2026 Saudi Arabian case series noted that palatability and sodium-load concerns associated with sodium-based predecessors prompted clinicians to favor glycerol phenylbutyrate. Adherence remains a key consideration, as daily doses can be substantial relative to body weight. Consequently, oral formulations are expected to remain the leading route of administration in the argininosuccinic aciduria market.

Enteral tube administration is forecast to grow at a CAGR of 6.4% through 2032. This route addresses the treatment requirements of neonates and infants who cannot reliably take medications orally. Neonatal metabolic units can administer liquid nitrogen scavengers through feeding tubes, facilitating consistent treatment for medically complex pediatric patients. In 2025, Zevra published information on administering OLPRUVA through a gastrostomy tube. Intravenous administration remains primarily limited to hospital settings for acute hyperammonemia rescue. Overall, the route mix reflects care requirements across the patient journey, ranging from long-term home-based treatment to emergency stabilization.

Geography Analysis

North America

North America accounted for 42.7% of the argininosuccinic aciduria market share in 2026, maintaining the largest regional position. The region benefits from well-established specialist metabolic care networks, orphan-drug reimbursement frameworks, and high per-patient treatment expenditure. Lupin reported annual sales of USD 337 million for the reference glycerol phenylbutyrate product for the year ended December 2025. Endo launched the first generic glycerol phenylbutyrate liquid in the United States in October 2025, while Lupin’s approval in May 2026 introduced an additional generic alternative. This evolving mix of branded and generic products is expected to keep market access and pricing under close payer scrutiny.

Asia-Pacific is forecast to grow at a CAGR of 4.7% through 2032. Japan represents a key access market, following Ravicti’s national health insurance listing and launch in April 2026. The listed price was JPY 41,455.4 per unit. China is strengthening its diagnostic capacity through regional newborn screening programs. A 2025 study in Xinjiang reported expanded screening of 107,741 neonates between 2019 and 2024 using tandem mass spectrometry^[2]. This infrastructure can enhance the identification of inherited metabolic disorders and support earlier intervention. Although Asia-Pacific remains smaller than North America, continued investments in screening and patient access programs underpin its stronger growth outlook.

The Rest of the World remains an early-stage region within the argininosuccinic aciduria market. Immedica received approvals for Ravicti in the United Arab Emirates and Oman in March 2026, following earlier Gulf Cooperation Council approvals in Saudi Arabia, Kuwait, and Qatar. This phased regulatory expansion illustrates how regional licensing strategies can broaden rare-disease access across multiple markets. In Latin America and Sub-Saharan Africa, inconsistent newborn screening may delay diagnosis and restrict regular access to therapy. Available evidence identifies underdiagnosis as a key market barrier in regions where screening infrastructure and specialist care capabilities remain uneven.

Asia-Pacific

Asia-Pacific is forecast to grow at a CAGR of 4.7% through 2032. Japan represents a key access market, following Ravicti’s national health insurance listing and launch in April 2026. The listed price was JPY 41,455.4 per unit. China is strengthening its diagnostic capacity through regional newborn screening programs. A 2025 study in Xinjiang reported expanded screening of 107,741 neonates between 2019 and 2024 using tandem mass spectrometry.

Rest of the World

The Rest of the World remains an early-stage region within the argininosuccinic aciduria market. Immedica received approvals for Ravicti in the United Arab Emirates and Oman in March 2026, following earlier Gulf Cooperation Council approvals in Saudi Arabia, Kuwait, and Qatar. This phased regulatory expansion illustrates how regional licensing strategies can broaden rare-disease access across multiple markets. In Latin America and Sub-Saharan Africa, inconsistent newborn screening may delay diagnosis and restrict regular access to therapy. Available evidence identifies underdiagnosis as a key market barrier in regions where screening infrastructure and specialist care capabilities remain uneven.